Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates 1

• 2625 alphaTIGIT-guided IL-15 mimetics enable potent and safe antitumor immunity Xiangming Liu, Nan Li, Yang-Xin Fu, Zaopeng Yang
• 2626 A cleavable IL10-TCE counteracts TCE-induced T cell dysfunction and eradicates solid tumors without toxicity Xinxin Wang, Yang-Xin Fu, Zaopeng Yang
• 2627 ALX006, a PD-1/VEGF bispecific antibody with best-in-class potential demonstrates superior antitumor activity and favorable PK in preclinical models Zenglin Pei, Yupeng Zhu, Jinglu Xia, Zhaojun An, Barry Duplantis, Yuhao Wang, Yali Wang, Jia Ge, Xiaojin Zhang, Lingjian Yang, Liang Du, Xiangyu He, Yi Li
• 2628 AM109, a PSMA×CD137 bispecific antibody with target-dependent T cell activation and potent anti-tumor activity in prostate cancer Dong-Wook Kim, Hyun-Jong Lee, Seong Yeol Kim, Min Yoon, Youngha Lee, In-Sik Hwang, Yoon Lee, Jong-Hoon Kim, Jong-Seo Lee
• 2629 · PDF A novel ADAM9 ADC with robust anti-tumor efficacy and remarkable preclinical safety profile Ruirui Sui, Yin Lu, Furong Gao, Chen Xu, Jiangbo Song, Guoping Jiang, Liuge Gu, Teddy Yang, Ying Lei, Li Tong, Fei Peng
• 2630 MRG008: A novel EGFR and 5T4 bispecific antibody-drug conjugate (ADC) with potent antitumor activity in preclinical studies Yuanyuan Yang, Zhijian Cai, Deliang Li, Shoujia Liu, Wenci Gong
• 2631 · PDF LPD002, a novel anti-PD-1/IL-2 fusion protein, demonstrates potent antitumor activity in preclinical studies Xiaoli Zhang, Zhijian Cai, Shoujia Liu, Wenci Gong
• 2632 DXP-106, an anti-IL1RAP monoclonal antibody with enhanced ADCC activity, exhibits both in vitro and in vivo anti-tumor effects and has successfully completed IND-enabling studies Qinghao Liu, Yaqi Ru, Yan Jiang, Huimin Li, Wenbo Li, Lan Yang, Qian Shi
• 2633 · PDF A T-cell engager antibody targeting the non-shed site of mesothelin in solid tumors Eber Antonio Guzman-Cruz, Masanori Onda, Xiufen Liu, Tara O’Shea, Qi Zhou, Wenlong Liu, Jing Bian, Chin-Hsien Tai, Ira Pastan, Mitchell Ho
• 2634 · PDF HEC-922:A CDH17-4-1BB bispecific antibody targeting CDH17 positive tumors shows potent anti-tumor activity Junji Dong, Shushan Lin, Zhou Linjun, Jiang Qiuyue, Chen Cangsha, He Shuiqing, Xiang Li, Ju Peng, Xiaohui Li, Cai Zhao, Ming Li, Xiaoping Li, Stewart Leung
• 2635 Novel tumor microenvironment (TME) activated interleukin-2 (IL-2) fused to anti-PD-1 or anti-PD-1/VEGF-A antibodies for enhanced anti-tumor immunity Rui Zhang, Cheng Liu, Yuan Liu
• 2636 Tumor microenvironment-activated T-cell engager (TMEA-TCE) targeting claudin 6 demonstrates efficacy without inducing cytokine release syndrome Chengli Ding, Cheng Liu, Yuan Liu
• 2637 · PDF A DR5-targeting ADC exhibits superior anti-tumor activity and potentially better therapeutic window Yang Wang, Lixia Cao, Cui Feng, Yifan Yang, Fangdun Jiang, Lixia Gu, Qi Zhang, Chen Li, Ming Zhou, Cancan Li, Wei Huang, Bonan Yan, Ziping Wei, Yuhong Zhou
• 2638 · PDF A rapid patient-derived organoids platform guides the evaluation of ERBB-targeting bispecific T-cell engagers Yuhong Liu, Chen Wang, Jing Zhao, Leli Zeng
• 2639 · PDF Mesothelin-targeted nanobody-drug conjugates to treat pancreatic cancer Nisita Dutta, Roman Misteli, Jessica Hong, Julie Becher, Francisco Corzana Lopez, Christine Alewine, Mitchell Ho, Gonçalo Bernardes
• 2640 XmAb808, a B7H3-targeted CD28 bispecific antibody, costimulates T cells enhancing the anti-tumor activity of clinically active CD3 T cell engagers Michael Hedvat, Veronica Zeng, Mayra Montes-Camacho, Charles G. Bakhit, Alex K. Lam, Lizett E. Scott, Jessica Reyes, Heather P. Jimenez, Rosio Padilla, Scott Taylor, Jose Serrato Bucio, Matthew A. Dragovich, Sung-Hyung Lee, Katrina Bykova, Yoon K. Kim, Suzanne Schubbert, Christine Bonzon, Seung Y. Chu, Gregory L. Moore, F. Rena Bahjat, John R. Desjarlais
• 2642 Pan-cancer GlyTR1 CAR T cells with ‘velcro-like' density-dependent targeting of beta1,6GlcNAc-branched N-glycans Paresh Kumar Purohit, Raymond W. Zhou, Michael Demetriou
• 2643 Clinical predictors of cytokine release syndrome in non-single chain CD3 directed therapies among cancer patients Harshit Khosla, Brian Dinh, Rodney Hunter, Neha Maithel, Natalie Rafaeli, Sara Taveras, Joan Marie C Bull, Syed H. Jafri, Adan Rios
• 2644 · PDF Enhancing safety to unlock efficacy: A novel class of conditionally-activated T cell engagers for solid tumors Aude Segaliny, Than Thar Aye, Randall Bettman, Jui-Yi Chen, Yang Zhou, Xiaoya Jessie Ma, Rodrigo Rivera, Ricky Cheng, Xianzhi Jiang, Yonglei Shang, George Wu
• 2645 · PDF Characterization of osemitamab in pancreatic cancer models and patients Fei Teng, Huanhuan Guo, Di Sun, Xinlai Yao, Lei Shi, Yi Gu, Chuan Qi, Xueming Qian

在完整检索应用中浏览本分会场 →